JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M607951200 on January 8, 2007

J. Biol. Chem., Vol. 282, Issue 10, 7287-7298, March 9, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/10/7287    most recent
M607951200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, G.
Right arrow Articles by Zhao, R. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, G.
Right arrow Articles by Zhao, R. Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phosphatase Type 2A-dependent and -independent Pathways for ATR Phosphorylation of Chk1*Formula

Ge Li{ddagger}, Robert T. Elder§, Kefeng Qin{ddagger}, Hyeon Ung Park{ddagger}, Dong Liang{ddagger}, and Richard Y. Zhao{ddagger}§||1

From the {ddagger}Department of Pathology, Department of Microbiology-Immunology, ||Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201 and §Children's Memorial Research Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60614

ATM and Rad3-related (ATR) is a regulatory kinase that, when activated by hydroxyurea, UV, or human immunodeficiency virus-1 Vpr, causes cell cycle arrest through Chk1-Ser345 phosphorylation. We demonstrate here that of these three agents only Vpr requires protein phosphatase type 2A (PP2A) to activate ATR for Chk1-Ser345 phosphorylation. A requirement for PP2A by Vpr was first shown with the PP2A-specific inhibitor okadaic acid, which reduced Vpr-induced G2 arrest and Cdk1-Tyr15 phosphorylation. Using small interference RNA to down-regulate specific subunits of PP2A indicated that the catalytic beta-isoform PP2A(Cbeta) and the A regulatory {alpha}-isoform PP2A(A{alpha}) are involved in the G2 induction, and these downregulations decreased the Vpr-induced, ATR-dependent phosphorylations of Cdk1-Tyr15 and Chk1-Ser345. In contrast, the same down-regulations had no effect on hydroxyurea- or UV-activated ATR-dependent Chk1-Ser345 phosphorylation. Vpr and hydroxyurea/UV all induce ATR-mediated {gamma}H2AX-Ser139 phosphorylation and foci formation, but down-regulation of PP2A(A{alpha}) or PP2A(Cbeta) did not decrease {gamma}H2AX-Ser139 phosphorylation by any of these agents or foci formation by Vpr. Conversely, H2AX down-regulation had little effect on PP2A(A{alpha}/Cbeta)-mediated G2 arrest and Chk1-Ser345 phosphorylation by Vpr. The expression of vpr increases the amount and phosphorylation of Claspin, an activator of Chk1 phosphorylation. Down-regulation of either PP2A(Cbeta) or PP2A(A{alpha}) had little effect on Claspin phosphorylation, but the amount of Claspin was reduced. Claspin may then be one of the phosphoproteins through which PP2A(A{alpha}/Cbeta) affects Chk1 phosphorylation when ATR is activated by human immunodeficiency virus-1 Vpr.


Received for publication, August 18, 2006 , and in revised form, January 5, 2007.

* This study was supported in part by National Institute of Health Grants AI40891 and GM63080 (to R. Y. Z.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S5.

1 To whom correspondence should be addressed: Dept. of Pathology, University of Maryland School of Medicine, 10 South Pine St., MSTF700A, Baltimore, MD 21201. Tel.: 410-706-6301; Fax: 410-706-6302; E-mail: rzhao{at}som.umaryland.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Ashwell and S. Zabludoff
DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
Clin. Cancer Res., July 1, 2008; 14(13): 4032 - 4037.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. Huard, R. T. Elder, D. Liang, G. Li, and R. Y. Zhao
Human Immunodeficiency Virus Type 1 Vpr Induces Cell Cycle G2 Arrest through Srk1/MK2-Mediated Phosphorylation of Cdc25
J. Virol., March 15, 2008; 82(6): 2904 - 2917.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. L. DeHart and V. Planelles
Human Immunodeficiency Virus Type 1 Vpr Links Proteasomal Degradation and Checkpoint Activation
J. Virol., February 1, 2008; 82(3): 1066 - 1072.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.